Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Wegener granulomatosis.

C A Langford1

  • 1Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. clangford@niaid.nih.gov

The American Journal of the Medical Sciences
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clinical and experimental immunology·2017
Same author

Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.

Arthritis & rheumatology (Hoboken, N.J.)·2015
Same author

Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.)·2014
Same author

Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.

Arthritis and rheumatism·2013
Same author

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides.

Arthritis and rheumatism·2012
Same author

Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.

Clinical and experimental immunology·2011
Same journal

Providers' Perspectives on Hospital-Based Tobacco Treatment Efforts.

The American journal of the medical sciences·2026
Same journal

In Memoriam: Maurice A. Mufson, MD, MACP.

The American journal of the medical sciences·2026
Same journal

Outcomes of Acute Myeloid Leukemia Patients Admitted to the Intensive Care Unit within 100 days of Allogeneic Hematopoietic Stem Cell Transplantation.

The American journal of the medical sciences·2026
Same journal

Association Between Reverse Triiodothyronine and Cardiac Complications in Patients with Uncontrolled Graves' Disease.

The American journal of the medical sciences·2026
Same journal

Chlorthalidone vs. hydrochlorothiazide in hypertension management: Lessons for guiding clinical practice.

The American journal of the medical sciences·2026
Same journal

The impact of COVID-19 on alcohol-associated hepatitis and alcohol-associated cirrhosis.

The American journal of the medical sciences·2026
See all related articles

Wegener granulomatosis (WG) is an autoimmune disease causing inflammation and tissue damage in airways, lungs, and kidneys. Effective treatment with cyclophosphamide and glucocorticoids has improved outcomes, though challenges remain.

Area of Science:

  • Rheumatology
  • Immunology
  • Pathology

Background:

  • Wegener granulomatosis (WG) is a necrotizing, granulomatous vasculitis affecting the upper airways, lungs, and kidneys.
  • Vascular inflammation and occlusion leading to tissue ischemia are hallmarks of WG.
  • The precise mechanisms initiating WG remain largely unknown, with no established links to genetic, infectious, or environmental factors.

Purpose of the Study:

  • To characterize the clinical and pathological features of Wegener granulomatosis.
  • To review the historical context and evolution of understanding WG.
  • To discuss the impact of cyclophosphamide and glucocorticoid therapy on WG management.

Main Methods:

  • Literature review of historical case reports and clinical observations.

Related Experiment Videos

  • Pathological examination of affected tissues.
  • Analysis of treatment outcomes and patient follow-up data.

    • Main Results:

    • WG is characterized by vascular inflammation, occlusion, and subsequent tissue ischemia.
    • Early cases reported in the 1930s described distinct clinical and pathological findings.
    • Cyclophosphamide and glucocorticoids have become the standard treatment, transforming WG from a uniformly fatal disease to a manageable condition.

    Conclusions:

    • WG is a serious autoimmune vasculitis with significant impact on multiple organs.
    • While current therapies are effective, drug toxicity and disease relapse are ongoing concerns.
    • Long-term patient follow-up is crucial for understanding WG and optimizing treatment strategies.